Ovid Therapeutics (OVID) Capital Expenditures (2016 - 2024)
Ovid Therapeutics' (OVID) quarterly Capital Expenditures came in at -$26000.0 in Q4 2024, down 137.14% YoY from $70000.0 in Q1 2024, and down 126.8% on a QoQ basis from $97000.0 in Q2 2024.
Ovid Therapeutics (OVID) Capital Expenditures (2016 - 2024) Analysis & Trends
Ovid Therapeutics (OVID) has 9 years of Capital Expenditures data on file, last reported at -$26000.0 in Q4 2024.
- Quarterly Capital Expenditures fell 137.14% year-over-year to -$26000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$26000.0 (down 113.98% YoY) and the FY2024 annual result came in at $90000.0, down 7.22% from the prior year.
- Capital Expenditures retreated to -$26000.0 in Q4 2024, from $97000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q2 2022 to a low of -$26000.0 in Q4 2024.
- A 5-year average of $103268.2 and a median of $23759.0 in 2020 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 9067.26% — and 2024, when it sank 137.14%.
- Tracing OVID's Capital Expenditures over 5 years: stood at $178083.0 in 2020, then retreated by 9.05% to $161958.0 in 2021, then fell by 25.94% to $119939.0 in 2022, then sank by 41.64% to $70000.0 in 2023, then slumped by 137.14% to -$26000.0 in 2024.
- The last three Capital Expenditures figures came in at -$26000.0 (Q4 2024), $97000.0 (Q2 2024), and $19000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -26,000.00 |
| Dec 31, 2024 | -26,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 119,939.00 |
| Dec 31, 2022 | 119,939.00 |
| Sep 30, 2022 | 18,600.00 |
| Sep 30, 2022 | 18,600.00 |
| Jun 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 1.06 Mn |